ENGINEERING MEDICINES TO IMPROVE PATIENT CARE Investors News Releases Year None20232022202120202019201820172016 February 6, 2023 Viridian Appoints Scott Myers as President and Chief Executive Officer February 2, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) January 8, 2023 Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED) January 5, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 3, 2023 Viridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Displaying 21 - 25 of 25
Year None20232022202120202019201820172016 February 6, 2023 Viridian Appoints Scott Myers as President and Chief Executive Officer February 2, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) January 8, 2023 Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED) January 5, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 3, 2023 Viridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Displaying 21 - 25 of 25
February 2, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
January 8, 2023 Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)
January 5, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 3, 2023 Viridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference